Supernus Pharmaceuticals and Indivior are combining in an all-stock merger of equals, creating a mid-sized drugmaker focused entirely on the brain and central nervous system.
Announced August 3, 2026, the deal gives Supernus shareholders 1.54 Indivior shares for each share held, leaving Indivior holders with about 56.5% of the combined company and Supernus holders roughly 43.5%.
Before closing, Indivior will pay a one-time $1 billion special dividend, funded partly by $650 million in new debt. The merged company keeps the Supernus, Inc. name, trades on Nasdaq as SUPN, and is based in Rockville, Maryland. Expected to close in Q4 2026.
What each side brings
Supernus (2025 revenue $718.9 million) markets treatments for ADHD, Parkinson’s and depression, including Qelbree for ADHD and, via its 2025 Sage Therapeutics purchase, Zurzuvae for postpartum depression.
Indivior (2025 revenue $1.2 billion) leads in opioid use disorder, with the long-acting injectable Sublocade and the film Suboxone.
Why the commercial fit works
Both portfolios reach psychiatric and neurological prescribers, and that overlap is the operational logic.
ADHD, depression and opioid use disorder are treated substantially by the same specialties — psychiatrists, addiction medicine physicians, and primary care clinicians managing behavioural health. A sales organisation already visiting those prescribers can carry additional products at low marginal cost.
Both also involve controlled substances, which brings shared infrastructure requirements: DEA registration, prescription monitoring, restricted distribution and specific compliance obligations. That is expensive to build and cheap to reuse.
The Sublocade dependence
Indivior’s position rests heavily on the transition from Suboxone to Sublocade, which is worth understanding.
Suboxone is a daily film dissolved under the tongue, long off patent and facing generic competition that eroded its economics. Sublocade is a monthly injection delivering the same active drug, administered in a clinical setting.
The clinical argument for the injectable is adherence: a patient with opioid use disorder taking a daily medication can miss doses at exactly the moments when relapse risk peaks, whereas a monthly injection removes that daily decision entirely.
It also carries lower diversion risk, since nothing is dispensed for the patient to keep — a persistent concern with take-home buprenorphine that shapes how restrictively it is prescribed.
What the special dividend signals
Paying $1 billion out to shareholders before closing, partly with borrowed money, is a substantial structural feature rather than a detail.
It effectively returns cash to Indivior holders ahead of the combination, adjusting the economic split beyond what the share exchange ratio alone conveys — a mechanism commonly used when two companies with different cash positions merge and one side’s shareholders should be compensated for what they bring.
Funding it partly with new debt means the combined company begins more leveraged than either was alone, which constrains flexibility for future acquisitions or research investment.
The combined company
Together they will have 11 marketed drugs, roughly $2.2 billion in trailing 12-month revenue, and about $888 million in pro forma annual earnings after a targeted $125 million in yearly cost savings.
Supernus CEO Jack Khattar — who will lead the combined firm, with Indivior’s Tony Kingsley as board chair — called it “the ideal time” to build “a very powerful combination that otherwise would not exist.”
Where mid-sized specialists sit
The strategic logic is about scale in a specific therapeutic area rather than size generally.
The policy backdrop for opioid treatment
Indivior’s business sits inside a regulatory environment that has changed substantially and could change again, which is a real variable in the combined company’s outlook.
Buprenorphine prescribing was long restricted in the United States by a requirement that clinicians obtain a special waiver involving additional training and patient caps. That requirement was eliminated, allowing any clinician with prescribing authority to treat opioid use disorder with it.
The intent was to expand access to a treatment that reduces overdose death substantially and reaches a minority of those who need it. The effect on uptake has been real but slower than hoped, since removing a legal barrier does not by itself make clinicians comfortable treating addiction.
Reimbursement is the other lever. Coverage for medication-assisted treatment has broadened, and a monthly injectable administered in a clinical setting is billed differently from a prescription filled at a pharmacy — which affects both the economics and which settings can realistically offer it. A company whose growth depends on that transition is exposed to decisions made well outside its control.
A $2.2 billion CNS-focused company is too small to compete with large pharmaceutical firms across many areas, and large enough to be the significant commercial partner in its own. That matters when licensing assets from smaller developers who need a commercial route but do not want to be one product among hundreds. Business news, not investment advice.